Sunday, 16 August 2026European Markets
ExploreSearch
ViaNews EU
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Move to Shore Up Trust as Leadership Shifts and AI-Adjacent Markets Wobble
Major AI and media platforms are converging on trust and accountability measures — Anthropic's Claude adding watermarks, Spotify labeling AI artists — just as OpenAI loses special-projects lead Brad Lightcap and Meta's Zuckerberg publishes a defensive manifesto on AI's societal role. In parallel, AI-adjacent financial dynamics are surfacing real stress: Wall Street firms are paying for privileged early access to Trump's Truth Social posts for trading edge, while Trump Media itself reports a $238M loss driven by falling crypto holdings, highlighting how information asymmetry and speculative digital assets are becoming entangled with AI-era platforms.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,809
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,809 facts checked against source5,205 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 6, 2025

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

View original at finance.yahoo.com
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors Findings from the Phase 3 study were presented at the 67th American Society of Hematology Annual Meeting and Exposition and published in Blood NEW YORK, December 06, 2025--(BUSI…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Approximately 20% of people with hemophilia A and 3% of people with hemophilia B develop inhibitors to factor replacement therapies

    80% confidence

  • The data demonstrate the potential of HYMPAVZI to combine efficacy, safety, and straightforward administration for adults and adolescents living with hemophilia A or B with inhibitors

    80% confidence

  • Pfizer continues its ongoing effort spanning more than 40 years to improve hemophilia care

    80% confidence

  • The emergence of inhibitors poses significant treatment challenges and can increase disease burden for people living with hemophilia A or B

    80% confidence

  • More than 800,000 people in the world live with hemophilia A or hemophilia B

    80% confidence

  • HYMPAVZI reduced bleeds by 93% compared to on-demand treatment with bypassing agents in adults and adolescents with hemophilia A or B with inhibitors

    80% confidence

  • HYMPAVZI demonstrates potential as a safe and efficacious treatment option that significantly reduced bleeding episodes and improved certain aspects of health-related quality of life

    80% confidence

Data points we hold from this source

Pfizer Inc. · hemophilia research duration40 years
Pfizer Inc. · company age175 years
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors — Source | Via News | ViaNews EU